A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephen Huang, MD
Alnylam Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clinical Trial Site
Adelaide, South Australia, Australia
- Clinical Trial Site
Fitzroy, Victoria, Australia
- Clinical Trial Site
Parkville, Victoria, Australia
- Clinical Trial Site
Hong Kong, Hong Kong
- Clinical Trial Site
Auckland, New Zealand
- Clinical Trial Site
Singapore, Singapore
- Clinical Trial Site
Seoul, South Korea
- Clinical Trial Site
Seoul, South Korea
- Clinical Trial Site
London, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Jun 2016
- Primary completion
- 31 Oct 2017
- Completion
- 31 Oct 2017
- Last update posted
- 24 Sept 2018
- Registered enrollment
- 24
- Registry id
- NCT02826018
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.